Global Dry Eye Syndrome Market, By Product Type (Tear stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Drug Class (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2029.
Global Dry Eye Syndrome Market Analysis and Size
In recent years, the dry eye syndrome market is anticipated to grow rapidly during the forecast period. Dry eye illness affects a large percentage of the global population (from middle age to elderly age). According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. From 9.3 percent in 2020 to roughly 16.0 percent in 2050, the proportion of the population aged 65 and up is predicted to rise. The elderly population is expected to grow, and this group will need to be accommodated.
- Data Bridge Market Research analyses that the dry eye syndrome market was valued at USD 4.20 billion in 2021 and is expected to reach USD 7.38 billion by 2029, registering a CAGR of 7.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Dry Eye Syndrome Market Definition
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a condition in which the surface of the affected person's eyes lacks lubrication or moisture. It's a common ailment that can strike anyone at any time. Aching and burning sensations, sore eyes, red eyes, weary eyes, itchy eyes, photophobia, and other symptoms of dry eye can occur. Watery eyes can also be a symptom, as the dry surface of the eyes over-stimulates the production of the watery component of tears to compensate for the dryness.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Tear stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Drug Class (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Eli Lilly and Company (US), AstraZeneca (UK), Novartis AG (Switzerland), Johnson & Johnson Private Limited (US), Teva Pharmaceutical Industries Ltd.(Jerusalem), Merck & Co., Inc. (US), Allergan (Ireland), Bausch Health Companies Inc. (Canada), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Sanofi (France), Merck KGaA (Germany), Otsuka America Pharmaceutical, Inc. (US), Akorn Operating Company LLC (US), Allostera Pharma Inc. (Canada), I-Med Pharma Inc. (Canada), Santen Pharmaceuticals Co. Ltd., (Japan), AFT Pharmaceuticals (New Zealand), Novaliq GmbH (Germany)
|
|
Market Opportunities
|
|
Dry Eye Syndrome Market Dynamics
Drivers
-
Increasing Prevalence of Dry Eyes Among People
The rising prevalence of dry eyes among people is a primary driver of the dry eye syndrome market's growth. Thyroid disorders, lupus, Sjogren’s syndrome, diabetes, rheumatoid arthritis, scleroderma, and others are the various diseases contributing to the high prevalence of dry eyes among people.
-
Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of dry eye syndrome market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the dry eye syndrome market. Additionally, high disposable income and increasing demand for standard treatment will result in the expansion of dry eye syndrome market. Changing dietary pattern and sedentary lifestyle are the factors that will influence the market dynamics during the forecast period. Along with this, rising geriatric population and increasing awareness about dry eye problem among people will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the dry eye syndrome market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the dry eye syndrome market growth during the forecast period.
Restraints/Challenges Global Dry Eye Syndrome Market
On the other hand, the delay in drug approval process will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the dry eye syndrome market. Additionally, strict drug approval mechanisms of testing bodies resulting in the delay of launch of new drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This dry eye syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dry eye syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Dry eye syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Dry Eye Syndrome Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. The dry eye syndrome market was negatively impacted by COVID-19. The sudden rise in coronavirus infections caused healthcare staff to focus on coronavirus management, obscuring other instances. There was a shortage of eye care drugs on the market due to restrictions on the flow of products and people. Furthermore, it resulted in a decrease in the number of individuals seeking treatment in hospitals and clinics. However, internet medical consultation and pharmaceutical sales have seen a surge in popularity. Following the COVID-19 relaxations, the market is quickly recovering.
Recent Development
- In January 2022, Sun Pharma had announced the launch of dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nanomicellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.
Global Dry Eye Syndrome Market Scope
The dry eye syndrome market is segmented on the basis of product type, dosage type, drug class, dose, medication type, container type, packaging type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Tear stimulators
- Artificial Tears
- Secretagogue
- Others
On the basis of product type, the market is segmented into tear stimulators, artificial tears, secretagogue and others.
Dosage Type
- Liquid
- Semi-solid
- Others
On the basis of dosage type, the market is segmented into liquid, semi solid and others.
Drug Class
- Lubricating Agent
- Cholinergics
- Anti-Inflammatory
- Anti-Infectives
- Anti-Allergics
- Others
On the basis of drug class, the market is segmented into anti-inflammatory, lubricating agents, anti-infectives, anti-allergics, cholinergics and others.
Dose
- Unit dose
- Multi-dose
On the basis of dose, the market is segmented into multi dose and unit dose.
Medication Type
- Prescription (Rx) Drugs
- Over the Counter (OTC) Drugs
On the basis of medication type, the market is segmented into prescription (RX) drugs, and over the counter (OTC) drug.
Container Type
- Unit-Dose Vials
- Bottles
- Tubes
On the basis of container type, the market is segmented into unit dose vials, bottles, and tubes.
Packaging Type
- Plastic
- Aluminium
- Glass
On the basis of packaging type, the market is segmented into plastic, glass, and aluminium.
Type
- Brands
- Generics
On the basis of type, the market is segmented into generics and brands.
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
On the basis of end-users, the dry eye syndrome market is segmented into hospitals, specialty clinics, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the dry eye syndrome market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others.
Dry Eye Syndrome Market Regional Analysis/Insights
The Dry eye syndrome market is analysed and market size insights and trends are provided by country, product type, dosage type, drug class, dose, medication type, container type, packaging type, type, end-users and distribution channel as referenced above.
The countries covered in the Dry eye syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America and Europe dominate the dry eye syndrome market because of the growing prevalence of dry eye syndrome in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Dry Eye Syndrome Market Share Analysis
The Dry eye syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dry eye syndrome market.
Some of the major players operating in the dry eye syndrome market are:
- Teva Pharmaceutical Industries Ltd ( Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- AbbVie Inc. (US)
- Otsuka America Pharmaceutical, Inc. (US)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Merck KGaA (Germany)
- Allergan (Ireland)
- Akorn Operating Company LLC (US)
- Allostera Pharma Inc. (Canada)
- I-Med Pharma Inc. (Canada)
- Santen Pharmaceuticals Co. Ltd., (Japan)
- AFT Pharmaceuticals (New Zealand)
- Novaliq GmbH (Germany)
SKU-